Introduction
The often comorbid tics and compulsions in Tourette's syndrome (TS) and ObsessiveCompulsive Disorder (OCD) may involve overlapping or parallel brain circuits (Robertson, 2000; American Psychiatric Association, 2013) . A role for cortical and amygdalar glutamatergic output subcircuits of CSTC loops in eliciting or mediating neurogenic tics and compulsions was proposed late last century, then elaborated in the intervening two decades McGrath et al., 2000; Carlsson, 2000; Rosenberg et al., 2000; Nordstrom and Burton, 2002; Singer et al., 2010; Milad and Rauch, 2012; Nordstrom et al., 2015) . Functional MRI of TS shows primary hyperactivity of excitatory somatosensory, insular and efferent motor output circuits, which elicits premonitory urges and tics (Bohlhalter et al., 2006; Wang et al., 2011) , and secondary hypoactivity of motor-suppressing executive-control circuits (Swerdlow and Sutherland, 2005) . The latter may include depletion or deficiency of these regulatory interneuron populations: 1) cortical GABAergic inhibitory interneurons; 2) striatal (STR) cholinergic interneurons that normally excite GABAergic STR "indirect pathway" (IP) medium spiny neurons (MSNs) suppressing tics and compulsions; and 3) STR parvalbumin-positive GABAergic fast-spiking interneurons (FSIs) that normally inhibit GABAergic STR "direct pathway" (DP)
MSNs activating tics and compulsions (Kalanithi et al., 2005; Kataoka et al., 2010; Burguiere et al., 2013; Xu et al., 2015a) .
The frequent comorbidity of TS and OCD suggests their symptoms overlap not only in their interconnecting and parallel CSTC circuitry but also in their pathophysiology: Compulsions are usually preceded by obsessions and anxiety and involve orbitofrontal cortex (OFC) & amygdalar hyperactivity, while tics are preceded by discomfiting premonitory sensations & urges and involve OFC-interconnected somatosensory cortex & amygdalar hyperactivity; also, both show impaired sensorimotor gating, which normally filters out irrelevant inputs . Consequently, both OCD and TS involve hyper-attentiveness to the obsessions and/or urges, which are temporarily alleviated by performing the desired acts and/or motions, likely by feedback inhibition from prefrontal & motor cortex collaterals. Stress also aggravates both disorders, likely from hyperglutamatergic amygdalocortical output . Maladaptive habits also develop in both disorders, likely from overlap and parallelism of their CSTC circuitry, including their cortical & amygdalar elements and target dorsal striatum (STR) & ventral STR (nucleus accumbens, or NAc) elements, which modulate not only motor activity but urges, aversion vs. reward, and habit formation (Bortolato and Pittenger, 2017) .
Consistent with their parallel neuropathophysiology, both TS and OCD are associated with hyperactivity of regional (somatosensory or orbitofrontal) cortical output neurons, and deficient cortical inhibitory gating evidenced by PPI (prepulse inhibition) deficits (Swedo et al., 1992; Breiter et al., 1996; Ziemann et al., 1997; Edgley and Lemon, 1999; Gilbert et al., 2004; Mantovani et al., 2006; Swerdlow and Sutherland, 2006; Ahmari et al., 2012; Bortolato and Pittenger, 2017) . Transcranial magnetic stimulation confirms regional cortical disinhibition in both disorders (Ziemann et al., 1997; Gilbert et al., 2004; Mantovani et al., 2006) , while elevated corticostriatal glutamatergic efflux was confirmed in OCD (Rosenberg et al., 2000) . Similarly, both monkey and rat stereotaxic drug studies showed that disinhibiting sensorimotor corticostriatal glutamate (GLU) output was essential to generate tic-like symptoms, while inhibiting it was essential to diminish them (Pogorelov et al., 2015) . These findings suggested that corticostriatal GLU can elicit, not just mediate, TS and OCD symptoms.
CSTC loop hyperactivity in TS arises polygenically, most often from diffuse disruptions in synapse formation or function (Huang et al., 2017) , but may etiologically arise in some TS cases as impairment either of inhibitory interneurons (Verkerk et al., 2003; Minzer et al., 2004; Penagarikano et al., 2011) or of inhibitory neurotransmission. Absence of histamine may disinhibit nigrostriatal, striatal, and cortical output in Hdc (histidine decarboxylase) gene deletionassociated hyperdopaminergic forms of human TS or mouse TS-like orofacial and sniffing stereotypies (Ercan-Sencicek et al., 2010; Karagiannidis et al., 2013; Castellan Baldan et al., 2014; Xu et al., 2015b) . Diminished removal or reuptake of dopamine (DA) likewise triggers hyperdopaminergic TS-like and/or OCD-like symptoms in mice Fox et al., 2013) . But even these hyperdopaminergic etiologies involve STR immediate-early gene induction that still remains dependent on coincident GLU input (Rapanelli et al., 2014; Castellan Baldan et al., 2014) , suggesting DA and GLU coinduce STR output to mediate or elicit tics and compulsions. This is consistent with reported OCD-like symptoms in mice with genetic knockouts of Sapap3, a corticostriatal synapse protein that normally inhibits GLU-induced STR MSN output (Welch et al., 2007; Ting and Feng, 2008; Burguiere et al., 2013; Wan et al., 2014);  or of Slitrk5, which normally inhibits OFC hyperactivity (Shmelkov et al., 2010) .
Starting with the first transgenic "brain circuit-test" of behavior, I review the ongoing transgenic, optogenetic, and chemogenetic alterations of CSTC circuit element output to understand and treat the abnormal urge-& motor-symptoms of TS and comorbid OCD-spectrum disorders. These studies support the importance of CSTC subcircuit hyperactivation vs. inhibition in inducing vs. suppressing these psychomotor symptoms. Nordstrom and Burton, 2002) , were created with a neuropotentiating transgene that instead of directly depolarizing and firing neurons enhanced their responsiveness to their endogenous fast-acting neurotransmitters (Fig. 1) .
_____________________________________________________________________________
A decade before microbial channelrhodopsin-based optogenetics, this was achieved by DA D1 receptor (DRD1) gene promoter-targeted expression of a microbial exon encoding the exclusively intracellular A1 subunit of cholera toxin (CT) . Transgenic CT physiologically engineers cellular hyperactivity --and potentiates neurons --by covalently ADPribosylating their stimulatory Galpha-s protein (Gs), which chronically activates adenylate cyclase, elevating intracellular levels of the second messenger 3',5'-cyclic adenosine monophosphate (cAMP) (Burton et al., 1991; Zeiger et al., 1997) . Furthermore, in D1CT founder lineage 7, CT expression was regionally restricted to a cortical/limbic subset of D1+ neurons with no expression in striatal D1+ neurons . The potentiated cortical/limbic D1+ neurons induce glutamatergic hyperactivation of the same somatosensory, orbitofrontal, amygdalar, and efferent STR motor output circuits showing primary hyperactivity in human TS and OCD Bohlhalter et al., 2006; Wang et al., 2011; Church and Shlaggar, 2014) . Those circuits' chronic hyperactivation in the D1CT-7 mice similarly causes OCD-like perseveration of multiple complex behaviors , as well as TS-like twitches, leading to the mouse model's nickname, "Ticcy mice" (Nordstrom and Burton, 2002) . The D1CT-7 mice's perseveration of many otherwise normal behaviors is more complex than the stereotyped sniffing & locomotion that can be imposed upon normal (and even upon D1CT-7) mice by broadacting drugs like cocaine, which are thought to activate a broader set of parallel DA-responsive CSTC-subcircuits (Campbell et al., 1999c) . The D1CT-7 mice's chronic cortical-limbic GLU output to the STR also unbalances its STR DP vs. IP MSN output pathways in favor of DP MSN output, yet confers behavioral supersensitivity to D2 antagonists, the first drug class shown to be therapeutic for TS & OCD Nordstrom and Burton, 2002; Nordstrom et al., 2015) . The mice also show TS-& OCD-like symptom exacerbation by stress Godar et al., 2016) , TS-like temporary supressibility of twitching, juvenile onset of twitching, more severe & frequent twitching in males (Nordstrom and Burton, 2002) , and alleviation of twitching by clonidine, a second pharmacological class of TS therapeutic drug (Nordstrom and Burton, 2002; Campbell et al., 1999b) . These traits are among the greatest behavioral similarities to TS & OCD of animal models reported to date (Burke and Lombroso, 2004; Pittenger et al., 2011) . The D1CT-7 mice's potentiated cortical circuitry is glutamatergic:
Although neither normal nor D1CT-7 mice show spontaneous seizures, normal mice show sloweronset & calmer pentylenetetrazole-kindled (cortical glutamatergic) seizures , as well as less-pronounced glutamatergic drug-induced locomotion than do D1CT-7 mice . Based on their specific neuropotentiated somatosensory & limbic CSTC circuit elements (Table 1) , D1CT-7 mice comprised a direct test of the hypothesis that cortico/amygdalo-striatal hyperglutamatergic output can cause tic-and compulsion-like behaviors Carlsson, 2000; Nordstrom and Burton, 2002) .
Early awareness of the D1CT-7 hyperglutamatergic CSTC model (Sah and Sallee, 2002; Burke and Lombroso, 2004; Joel, 2006; Ting and Feng, 2008; Wang et al., 2009; Pittenger et al., 2011; Wu et al., 2012; Ahmari and Dougherty, 2015) helped spur clinical studies of GLU's role in TS and OCD (Chakrabarty et al., 2005; Singer et al., 2010) and new drug trials for TS, OCD, and OCD-spectrum disorders. These included successful trials of antiglutamatergics for OCD and trichotillomania (TTM) (Lafleur et al., 2006; Grant et al., 2007; Grant et al., 2009) . A D1 antagonist, potentially able to inhibit both D1+ cortical-limbic neurons' induced GLU output and D1+ STR DP MSN output, proved effective for TS (Gilbert et al., 2014) as well as for OCDspectrum gambling disorder (Grant et al., 2014) . And a neurosteroid inhibitor of D1+ corticostriatal subcircuits known to activate STR DP MSN output alleviated TS (Bortolato et al., 2007; Bortolato et al., 2008; Muroni et al., 2011; Frau et al., 2013; Frau et al., 2016) . D1CT-7 mice have since been used to identify new classes of prospective CSTC "circuit-breaker" drugs able to block TS-like symptoms (Nordstrom et al., 2015) .
Most recently, D1CT-7 mice were shown to exhibit stress-induction of multiple TS-& OCD-like symptoms, and to exhibit a sensorimotor gating deficit --impaired prepulse inhibition (PPI) --that increases its face validity as a model of the impaired sensorimotor gating in TS (Godar et al., 2016; Godar and Bortolato, 2017; Bortolato and Pittenger, 2017) Moreover, new methods for characterizing TS-like motor symptoms --microsecond-resolution force-plate actometer tests of mouse gait, and sticky-tape removal tests of sensorimotor integration --revealed stress-aggravated hyper-vigorous gait and sensorimotor integration deficits in D1CT-7 mice that match those reported for TS (Fowler et al., 2017) (Table 1) . These D1CT-7 mouse findings will help define how topographically overlapping and parallel CSTC loop abnormalities manifest urge-or obsession-driven psychomotor, sensorimotor, locomotor, and compulsive symptoms in TS & OCD-spectrum disorders. In turn this will also shed light on other CSTC loop- However, the D1CT-7 mouse model circuit test is experimentally limited in that its chronic cortical-limbic D1+ neuropotentiation can't be deactivated or further spatially or temporally restricted (Fig. 1) . Although the chronic nature of this mouse's potentiated forebrain GLU output likely contributes to its marked symptomatic resemblance to the similarly chronic disorders TS & OCD (Ahmari et al., 2013) , it can't provide the precise behavioral circuit-testing of each CSTC circuit element required to query these individual elements' roles in these disorders. Consequently, since the first use in the '90s of neuropotentiating transgenes chronically expressed either globally in all neurons (Burton et al., 1998) or selectively in cortical-limbic D1+ neurons , newer circuit-tests have used chemical-or photic-regulated "chemogenetic" or "optogenetic" transgenic methods (Fig. 1) 
Optogenetic Channels
Scientists contributing to the first transgenic brain circuit-test using modified bacterial neuropotentiating transgenes ) later contributed to the first optogenetic brain circuit-tests using modified bacterial and algal photoactivatable or photoinhibitable channelrhodopsin, halorhodopsin, or archaerhodopsin neurostimulating or neuroinhibiting transgenes (Adamantidis et al., 2007; Tsai et al., 2009) . Rather than chronically potentiating genetically-specified neurons, optogenes (usually also stereotaxically-injected into different mouse brain regions on viral vectors) directly depolarize (fire) or hyperpolarize (silence) genetically-specified neurons in response to spatially-and temporally-restricted photon excitation from cranial fiber-optic leads or light-emitting diode (LED) implants. Optogenetic neurostimulatory ( Table 1) Upstream CSTC circuit elements optogenetically circuit-tested in mice include photostimulated GLU output from M1 and M2 motor CTX, OFC, and lateral OFC ( Table 1) ; and photoinhibited GLU output from infralimbic CTX ( Table 2) . Chronic (5-day) optogenetic neurostimulation of M2 motor CTX and OFC pyramidal projection neurons' GLU outputs to the STR respectively reproduced two TS-& OCD-like symptoms earlier seen in D1CT-7 miceincreased locomotion and perseverative grooming (Ahmari et. al., 2013) . In contrast, acute optogenetic neurostimulation of lateral OFC neurons that selectively excited not STR MSNs but mutant, functionally-deficient STR FSIs restored those FSIs' failed inhibition of OCD-like grooming in a gene knockout mouse model of OCD (Burguiere et al., 2013) . This interestingly suggests that corticostriatal GLU can excite not only STR MSN but also MSN-inhibiting STR interneurons, identifying a potential corticostriatal subcircuit for executive control (voluntary suppression) of tics and compulsions. Acute optogenetic stimulation of OFC output also confers OCD-like increased value to devalued acts (Gremel and Costa, 2013) , while acute optogenetic inhibition of infralimbic CTX GLU output neurons cancels new acquired habits & prevents their acquisition (Smith et al., 2012; Smith and Graybiel, 2013 (Kravitz et al., 2010) . More ventrally-located STR optogenetic stimulation of NAc D2+ IP MSN output inhibited OCD-like DA-entrained "compulsive" drug seeking/requesting (Bock et al., 2013) . Downstream of STR IP outputs, differential frequencies of optogenetic stimulation of STN neurons' GLU-responsive afferent fiber inputs reproduced both the motor activating vs. inhibiting effects of frequency-dependent deep-brain-stimulation (DBS) implants, and the effect of M1 motor CTX hyperdirect pathway GLU input to the STN (Gradinaru et al., 2009) . Optogenetic photoinhibition of another STR interneuron population, NAc cholinergic (ACH+) interneurons, indirectly increased NAc MSN output in a manner that specifically inhibited DA-drug reward-seeking/learning, while photostimulating these interneurons had no effect (Witten et al., 2010) .
Chemogenetic Designer Receptors
Other new brain circuit-testing techniques include stereotaxic viral vector-delivered transgenes encoding G-protein-coupled (stimulatory Gs-, Gs/olf-, or Gq-, and inhibitory Gi-coupled) "Designer Receptor Exclusively Activated by Designer Drugs" ("DREADDs") for drug-based "remote control" of receptor-coupled second messenger signaling (Rogan and Roth, 2011) (Fig.   1) . Such G-protein-coupled DREADD circuit-tests in rodents are confirming predicted roles for First, in mice, acute Gi-DREADD neuroinhibition of OFC GLU output, as predicted, disrupts any valuation of goal-directed acts, opposite to the OCD-like overvaluation of even useless acts that is conferred by optogenetic neurostimulation of OFC GLU output (Gremel and Costa, 2013) . Similarly, Gs-DREADD neurostimulation of STR & NAc IP MSNs reduces basal & novelty-induced locomotion and prevents its acute DA-drug sensitization (Farrell et al., 2013) , while Gi-DREADD neuroinhibition of NAc IP MSNs induces OCD-like "compulsive" (unrewarded and hypermotivated) drug-seeking/requesting (Bock et al., 2013) .
In rats, Gi-DREADD neuroinhibition of dorsal STR DP vs. IP MSNs similarly inhibits vs.
causes OCD-like increases in DA-drug sensitization/retention of locomotion (Ferguson et al., 2011) . Also, Gi-DREADD neuroinhibition vs. Gs-DREADD neurostimulation of dorsomedial STR DP MSNs inhibits vs. causes an OCD-like increase in retention of rewarding feeding strategies (Ferguson et al., 2013) . This latter study comparing Gi-vs. Gs-DREADD effects on the same neurons specifically implies that the level of cAMP-dependent neuropotentiation within dorsomedial STR DP MSNs mediates retaining reward-specific information needed to improve later performance --a process that when aberrantly excessive could engender compulsions.
Activity-Dependent Chemogenetic Designer Receptors
A new derivation of chemogenetic DREADD methods is now being used to further specify genetically-defined neurons by their prior synaptic-activation in response to drugs, electrical stimuli, or neurotransmitters --including neurotransmitter changes elicited by disease states. Expression of such "Activity-Dependent" DREADDs is achieved by using a synthetic "Enhanced Synaptic Activity-Responsive [DNA] Element" (E-SARE) to drive neuronal activitydependent gene expression of Cre-loxP recombinase to permanently assemble the DREADD transgene (Kawashima et al., 2013) . This approach has been elegantly used to reveal the roles in manifesting mouse TS-& OCD-like symptoms played only by those CTX or STR neurons that can be synaptically-activated by an actual known etiological cause of TS & OCD, loss of histamine neurotransmission ( Fig. 1; Table 1 & 2) . These studies functionally examined the medial prefrontal CTX (mPFC) neurons and dorsal STR neurons selectively supersensitized or synaptically activated by experimentally-reproduced genetic CNS histamine deficiency (Rapanelli et al., 2017a) , or by temporary Gi-DREADD-induced loss of hypothalamocortical & hypothalamostriatal histamine inputs (Rapanelli et al. 2017b ). Gs-DREADD neurostimulation of such histamine-depletion-activated mPFC neurons initiated "long-range" (ambulatory) locomotion, while that of histamine-depletion-activated dorsal STR neurons caused TS-& OCDlike stereotypic "short-range" locomotion, excess grooming, and head shakes (Table 1 & 2) .
Moreover, Gi-DREADD inhibition of these same neurons reverses the mice's histaminedeficiency dependent TS-& OCD-like behaviors ( Table 2) . Hence these hyperactivated CSTC circuit elements mediate not only twitches & urge-driven behaviors in mice, but likely also human tics & comorbid compulsions in at least one established etiological form of TS & OCD, which has polygenic etiologies (Huang et al., 2017) .
Back to the Future III: New Directions in TS & OCD Circuit Testing & Therapy

Future Circuit-Tests
Today's transgenic, optogenetic, and chemogenetic arsenal is ripe for fine-tuned CSTC circuittesting of not only feedforward cortical, amygdalar, STR, or STN circuit elements, but also feedback thalamocortical, thalamolimbic, and thalamostriatal circuit elements and their modulatory neurotransmitter inputs (Ellender et al., 2011; Halassa et al., 2014; Rapanelli et al., 2017a Rapanelli et al., , 2017b . STR neurons also include not only the currently investigated major DP & IP MSN output subpopulations and FSI or ACH+ interneuron subpopulations, but also STR NPY+ lowthreshold-spiking interneurons and STR interneurons defined by selective responsiveness to thalamic GLU instead of cortical/amygdalar GLU (Gerfen and Surmeier, 2011) . Circuit-testing these CSTC loop STR subpopulations will refine our understanding of the role of CSTC loop dysregulation in tics and compulsions. Also, new TS & OCD circuit-testing methods are in the offing, including not just neuromodulatory G-protein-coupled DREADDs but depolarizing-or hyperpolarizing-"channel-coupled" DREADDs, or "Pharmacologically Selective Actuator Molecules activated by Pharmacologically Selective Effector Molecules" (PSAMs-PSEMs) (Sternson and Roth, 2014) . Other new methods include neuromodulatory optogenes --optogenetic photon-activated G-protein-coupled receptors, or "optoXRs" (Airan et al., 2009) . Also, to bypass the potential issue of pharmacodynamic desensitization of optogenetic channels' or DREADD receptors' transmembrane domains, bacterial optogenetic adenylate cyclases have been developed (Ryu et al., 2010; Stierl et al., 2011) . These work like a photic-regulated version of the original circuit-testing neuropotentiation method, bacterial intracellular cholera toxin (Burton et al., 1991) .
Future Circuit-Therapies
Optogenetic channels' computer-programmed imposition of precise firing patterns on neurons is an optimal technique for brain-behavior circuit-testing. However, as a prospective therapeutic tool, it may risk reprogramming not only psychomotor urges but also normal behaviors unless combined with computerized monitoring-&-control implants analogous to next-generation DBS devices. As one alternative, neuropotentiating Gs-DREADDs would have less risk of robotizing behavior because they would only enhance targeted neurons' responsiveness to their own endogenous signals. Adeno-Associated Virus-(AAV-) delivery of Gs-DREADDs to somatosensory CTX or OFC D2+ inhibitory GABAergic "executive control" interneurons, or to STR IP D2+ "urge-& motor-suppressing" GABAergic output MSNs, could "bypass" the inhibitory effect of basal DA upon them. Their consequent designer-drug-neuropotentiation would then increase their ability to inhibit the intractable urges, premonitory sensations, obsessions, tics, movements, and compulsive habits they otherwise routinely fail to inhibit.
To illustrate the unprecedented utility of the newest chemogenetic methods, how might such a future "dopamine-bypass" gene therapy be constructed to work effectively in human patients requiring neurosurgical intervention? The enkephalin ENK gene promoter, which can abundantly express AAV-delivered DREADD transgenes in STR IP D2+ MSN GABAergic output neurons (Table 2) , isn't as abundantly expressed in the CTX D2+/parvalbumin+ GABAergic interneurons known to locally inhibit pyramidal GLU output neurons. But newly developed AAV-delivered DREADD transgenes using mouse or human Distal-less homeobox (hDlx) enhancers specifically confer, in the CTX as well as other telencephalon regions of multiple species, GABAergic neuron-specific DREADD expression (Dimidschstein et al., 2016) . 
In mouse somatosensory CTX, AAV-hDlx-GFP-expressed
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